Market Overview:
The global GLP analogs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising geriatric population, and technological advancements in the field of diabetes treatment. Based on type, the GLP analogs market is segmented into exenatide, liraglutide, lixisenatide, albiglutide, and dulaglutide. Exenatide currently dominates this market and is expected to maintain its dominance during the forecast period as well. Liraglutide held second-largest share in 2017 owing to its high efficacy and safety profile as compared with other drugs in this class.
Product Definition:
GLP Analogs are compounds that share a common chemical backbone with GLP-1, but have been modified to improve their pharmacokinetic and/or pharmacodynamic properties. Importance of GLP Analogs include: 1) improved metabolic stability; 2) longer half-life; 3) increased potency and receptor affinity; 4) reduced incretin effect (i.e., less pronounced glucose-lowering effects); 5) delayed gastric emptying; 6) reduced potential for pancreatitis.
Exenatied:
Exenatide (brand name Zirabev) is a once-a-day injectable drug used to treat GIT (Gastrointestinal Tract) disorders. It is marketed by Sun Pharmaceutical Industries Ltd. in India and China as a branded product and by Pfizer Inc. globally as an OTC drug under the brand name Silexane Mesylate. Exenatide was approved for GLP analogs treatment in 2015 in the U.S.
Liraglutide:
Liraglutide is a GLP-1 receptor agonist developed by Novartis AG. It was approved by the FDA in 2009 as a prescription drug for the treatment of type 2 diabetes and weight management. In 2014, it was approved as an over-the-counter (OTC) supplement under the brand name “Xenical” for use with diet and exercise to lower blood sugar in individuals with or at risk of developing type 2 diabetes mellitus.
Application Insights:
The other segment includes research institutes, industrial and healthcare applications. Other applications of glp analogs include hospital, pharmacy and others. Hospital application is expected to be the fastest-growing segment at a CAGR of XX% from 2018 to 2030 owing to rising awareness about weight loss among patients as a result of better management of chronic diseases such as diabetes and high blood pressure by reducing calorie intake through diet modification along with increasing exercise routine in obese patients.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of key players, such as Amgen Inc.; Takeda Pharmaceuticals North America LLC; and Novo Nordisk A/S. The region is expected to maintain its dominance over the forecast period due to increasing R&D activities and rising healthcare expenditure. In addition, growing awareness about products such as insulin analogs is expected to drive regional growth.
Asia Pacific market for glp analogs is anticipated to grow at a lucrative rate over the forecast period owing high unmet clinical needs coupled with rapidly improving economic conditions in emerging countries such as China & India are some of them).
In 2016, Novo Nordisk entered into a collaboration with Takeda Pharmaceutical Company Ltd., wherein it would provide access to its diabetes care solutions through Takeda's sales network across Asia Pacific.
Growth Factors:
- Increasing demand for GLP Analogs in the pharmaceutical and biotechnology industries for the development of novel drugs and therapies.
- Growing research and development investments in the field of GLP Analogs by pharmaceutical and biotechnology companies.
- Rising number of collaborations between academic institutions, research organizations, and pharmaceutical companies to develop novel GLP Analogs products.
- Technological advancements in the field of GLP Analogs that will help reduce manufacturing costs and improve product quality.
Scope Of The Report
Report Attributes
Report Details
Report Title
GLP Analogs Market Research Report
By Type
Exenatied, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide
By Application
Hospital, Pharmacy, Other
By Companies
Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb, Amylin
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global GLP Analogs Market Report Segments:
The global GLP Analogs market is segmented on the basis of:
Types
Exenatied, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
Highlights of The GLP Analogs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
- By Application:
- Hospital
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the GLP Analogs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
GLP analogs are medications that are similar to GLP-1 but have different properties. These medications can help improve blood sugar control in people with diabetes, and they may also be used to treat other conditions.
Some of the key players operating in the glp analogs market are Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb, Amylin.
The glp analogs market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. GLP Analogs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. GLP Analogs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. GLP Analogs Market - Supply Chain
4.5. Global GLP Analogs Market Forecast
4.5.1. GLP Analogs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. GLP Analogs Market Size (000 Units) and Y-o-Y Growth
4.5.3. GLP Analogs Market Absolute $ Opportunity
5. Global GLP Analogs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. GLP Analogs Market Size and Volume Forecast by Type
5.3.1. Exenatied
5.3.2. Liraglutide
5.3.3. Lixisenatide
5.3.4. Albiglutide
5.3.5. Dulaglutide
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global GLP Analogs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. GLP Analogs Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Pharmacy
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global GLP Analogs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. GLP Analogs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global GLP Analogs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. GLP Analogs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global GLP Analogs Demand Share Forecast, 2019-2026
9. North America GLP Analogs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America GLP Analogs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America GLP Analogs Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Pharmacy
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America GLP Analogs Market Size and Volume Forecast by Type
9.7.1. Exenatied
9.7.2. Liraglutide
9.7.3. Lixisenatide
9.7.4. Albiglutide
9.7.5. Dulaglutide
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America GLP Analogs Demand Share Forecast, 2019-2026
10. Latin America GLP Analogs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America GLP Analogs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America GLP Analogs Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Pharmacy
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America GLP Analogs Market Size and Volume Forecast by Type
10.7.1. Exenatied
10.7.2. Liraglutide
10.7.3. Lixisenatide
10.7.4. Albiglutide
10.7.5. Dulaglutide
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America GLP Analogs Demand Share Forecast, 2019-2026
11. Europe GLP Analogs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe GLP Analogs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe GLP Analogs Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Pharmacy
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe GLP Analogs Market Size and Volume Forecast by Type
11.7.1. Exenatied
11.7.2. Liraglutide
11.7.3. Lixisenatide
11.7.4. Albiglutide
11.7.5. Dulaglutide
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe GLP Analogs Demand Share, 2019-2026
12. Asia Pacific GLP Analogs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific GLP Analogs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific GLP Analogs Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Pharmacy
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific GLP Analogs Market Size and Volume Forecast by Type
12.7.1. Exenatied
12.7.2. Liraglutide
12.7.3. Lixisenatide
12.7.4. Albiglutide
12.7.5. Dulaglutide
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific GLP Analogs Demand Share, 2019-2026
13. Middle East & Africa GLP Analogs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa GLP Analogs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa GLP Analogs Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Pharmacy
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa GLP Analogs Market Size and Volume Forecast by Type
13.7.1. Exenatied
13.7.2. Liraglutide
13.7.3. Lixisenatide
13.7.4. Albiglutide
13.7.5. Dulaglutide
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa GLP Analogs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global GLP Analogs Market: Market Share Analysis
14.2. GLP Analogs Distributors and Customers
14.3. GLP Analogs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lily
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GSK
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol-Myers Squibb
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Amylin
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
